Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

13.25
-0.1800-1.34%
Post-market: 13.250.00000.00%19:30 EDT
Volume:68.36K
Turnover:905.87K
Market Cap:652.54M
PE:-8.47
High:13.64
Open:13.50
Low:13.07
Close:13.43
52wk High:17.82
52wk Low:8.75
Shares:49.25M
Float Shares:13.84M
Volume Ratio:0.81
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5649
EPS(LYR):-168.1598
ROE:-39.22%
ROA:-20.58%
PB:6.05
PE(LYR):-0.08

Loading ...

Company Profile

Company Name:
AgomAb Therapeutics
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
- -
Office Location:
Posthoflei 1/6,Antwerp,Antwerp,Belgium
Zip Code:
2600
Fax:
- -
Introduction:
AgomAb Therapeutics NV was originally incorporated on April 13, 2017 as a Belgian private limited liability company under Belgian law, and was converted into a Belgian limited liability company on March 14, 2019. The company is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical needs.

Directors

Name
Position
David Epstein
Chairman of the Board and Director
Tim Knotnerus
Chief Executive Officer and Executive Director
Angelika Jahreis
Non-Executive Director
Colin Bond
Non-Executive Director
Felice Verduyn van Weegen
Non-Executive Director
Ohad Hammer
Non-Executive Director

Shareholders

Name
Position
Tim Knotnerus
Chief Executive Officer and Executive Director
Pierre Kemula
Chief Financial Officer
Andrea Saez
Chief Development Officer
Ellen Lefever
General Counsel
Paul van der Horst
Chief Business Officer
Philippe Wiesel
Chief Medical Officer